SCHEMBL263229

SCHEMBL263229

[O]Cc1cccc2c1Cc1ccccc1-2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 1/20 0.68
DRD2 P14416 3/20 0.48
DRD4 P21917 2/20 0.48
DRD3 P35462 2/20 0.48
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
HTR7 P34969 2/20 0.43
HTR2B P41595 2/20 0.43
MAOA P21397 1/20 0.42
BCHE P06276 1/20 0.39
CES1 P23141 1/20 0.39
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
MAP3K9 P80192 1/20 0.37
MAP3K11 Q16584 1/20 0.37
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10749134 0.85 PNMT (0.64) PNMTDRD2DRD4DRD3NPC1
SCHEMBL633763 0.85 PNMT (0.68) PNMTDRD2DRD4DRD3NPC1
SCHEMBL30606684 0.85 PNMT (0.68) PNMTDRD2DRD4DRD3NPC1
SCHEMBL4910846 0.85 PNMT (0.68) PNMTDRD2DRD4DRD3NPC1
SCHEMBL7195192 0.84 PNMT (0.72) PNMTDRD2DRD4DRD3NPC1
SCHEMBL5366733 0.84 PNMT (0.72) PNMTDRD2DRD4DRD3NPC1
SCHEMBL7603814 0.82 PNMT (0.70) PNMTDRD2DRD4DRD3NPC1
SCHEMBL9859906 0.82 PNMT (0.70) PNMTDRD2DRD4DRD3NPC1
SCHEMBL7609046 0.82 PNMT (0.70) PNMTDRD2DRD4DRD3NPC1
SCHEMBL7607164 0.82 PNMT (0.70) PNMTDRD2DRD4DRD3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 547 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117924154-A Preparation method of piperidine-2-formate compound 浙江九洲药业股份有限公司 2024-04-26 CN claimed
CN-116685576-A Cysteine protease inhibitors and methods of use thereof 美商帕迪斯生物科学公司 2023-09-01 CN claimed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US claimed
EP-4161902-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2023-04-12 EP claimed
EP-4000623-A1 5-(2-(1H-INDOL-3-YL))-ETHYL)- PIPERAZIN-2-ONE DERIVATIVES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY VIRUSES OF THE FAMILY CORONAVIRIDAE Consejo Superior De Investigaciones Científicas (ES) 2022-05-25 EP claimed
WO-2022101293-A1 5-(2-(1H-INDOL-3-YL))-ETHYL)- PIPERAZIN-2-ONE DERIVATIVES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS BY VIRUSES OF THE FAMILY CORONAVIRIDAE CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2022-05-19 WO claimed
CN-114106324-A Polyamide acid solution and preparation method and application thereof 吉林奥来德光电材料股份有限公司 2022-03-01 CN claimed
WO-2021252644-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. (US) 2021-12-16 WO claimed
WO-2020225700-A1 COMPOUNDS HAVING A FUNGICIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND USE THEREOF FOR THE CONTROL OF PHYTOPATHOGENIC FUNGI ISAGRO S.P.A. (IT) 2020-11-12 WO claimed
EP-3444265-B1 PEPTIDE FOR SKIN REGENERATION OR WOUND TREATMENT AND USE THEREOF KINE SCIENCES CO LTD (KR) 2020-09-02 EP claimed
EP-0632026-A1 Alpha amino acid derivatives, a method for their preparation and pharmaceutical preparations containing them ADIR ET COMPAGNIE (FR) 1995-01-04 EP claimed
EP-0406567-B1 Process for the production of sulfonium compounds and novel methylthiophenol derivatives MITSUBISHI GAS CHEMICAL CO (JP) 1994-09-28 EP claimed
US-5159088-A Photinitiators for cationic polymerization BASF AKTIENGESELLSCHAFT (DE) 1992-10-27 US claimed
EP-0245662-B1 P-HYDROXYPHENYLSULFONIUM SALTS AND THEIR USE IN THE PREPARATION OF ESTERS AND AMIDES SANSHIN KAGAKU KOGYO CO., LTD. (JP) 1991-08-07 EP claimed
EP-0406567-A2 Process for the production of sulfonium compounds and novel methylthiophenol derivatives MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1991-01-09 EP claimed
EP-0375047-A2 New process for the synthesis of N alpha-fluorenylmethoxycarbonyl-Ng-trityl-arginine SCLAVO S.p.A. (IT) 1990-06-27 EP claimed
EP-0346756-A1 Process for production of sulfonium compounds MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1989-12-20 EP claimed
EP-0331988-A1 Sulfonium compounds, as well as process for producing active esters and amides used for the production of amides SANSHIN KAGAKU KOGYO CO., LTD. (JP) 1989-09-13 EP claimed
US-4857656-A Active esters used for production of esters or amides and process for producing esters or amides SANSHIN KAGAKU KOGYO CO., LTD. (JP) 1989-08-15 US claimed
EP-0245662-A1 p-Hydroxyphenylsulfonium salts and their use in the preparation of esters and amides SANSHIN KAGAKU KOGYO CO., LTD. (JP) 1987-11-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV PNMT 4164/4885DRD2 4609/4885DRD4 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.